LILRA2

Across TCGA pan-cancer cohorts, LILRA2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LILRA2 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LILRA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LILRA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC and GBM are the cancer types where LILRA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.885	0.448	.001	23	view →
GBM	OS	Tertile	All	0.741	0.903	.003	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LILRA2–PDAC (DFS)

Open the PDAC breakdown →